Dynavax Technologies Corp...

10.30
-0.35 (-3.29%)
At close: Apr 17, 2025, 3:59 PM
10.62
3.06%
After-hours: Apr 17, 2025, 06:25 PM EDT
-3.29%
Bid 10.24
Market Cap 1.28B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) 0.2
PE Ratio (ttm) 51.53
Forward PE 20.36
Analyst Buy
Ask 12.16
Volume 2,434,334
Avg. Volume (20D) 2,431,178
Open 10.75
Previous Close 10.65
Day's Range 10.26 - 10.76
52-Week Range 9.74 - 14.63
Beta 1.26

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...

Sector Healthcare
IPO Date Feb 19, 2004
Employees 405
Stock Exchange NASDAQ
Ticker Symbol DVAX
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 200.82% from the latest price.

Stock Forecasts

Next Earnings Release

Dynavax Technologies Corporation is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
-6.66%
Shares of vaccine stocks are trading lower after C... Unlock content with Pro Subscription
2 months ago
-3.79%
Dynavax shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell.